AI assistant
IMUGENE LIMITED — Capital/Financing Update 2025
Aug 10, 2025
65124_rns_2025-08-10_020c8af3-4bd0-4097-88a9-97bae9c36f61.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [177 x 31] intentionally omitted <==
ASX Announcement
Share Purchase Plan – Closing Date Extended
SYDNEY, Australia, 11 August 2025: Imugene Limited (ASX:IMU) ( Company ), refers to its ASX announcement on 16 July 2025 which announced the completion of a $22.5 million placement and the launch of a $15 million share purchase plan ( SPP ). The Record Date to be registered as an Eligible Shareholder for participation in the SPP was 15 July 2025.
The Company has received feedback that shareholders require further time to consider the SPP offer following the announcement released to the market last week (" 79% Overall Response Rate With Two Further Partial Responses "). Accordingly, the Company has determined to extend the SPP Closing Date to Monday, 25 August 2025 to allow shareholders more time to consider and respond to the SPP offer.
Updated SPP timetable
| Event | Date |
|---|---|
| Record Date for SPP (7.00pm, Sydney time) | Tuesday, 15 July 2025 |
| Announcement of Placement results and launch ofSPP | Wednesday, 16 July 2025 |
| Opening Date of SPP | Thursday, 24 July 2025 |
| Proposed EGM date for approval of SPP and NewOptions | Wednesday, 20 August 2025 |
| Closing Date for SPP | Monday, 25 August 2025 |
| Allotment of New Shares under the SPP andAttaching Options | Monday, 1 September 2025 |
| Last date for determining the eligibility ofPiggyback Options | Monday, 30 March 2026 |
The Company reserves the right to amend the above timetable, at its discretion, including for the purposes of any Australian Securities and Investments Commission (ASIC) and ASX requirements.
IMUGENE LIMITED ACN 009 179 551
WWW.IMUGENE.COM
==> picture [42 x 42] intentionally omitted <==
All other terms of the SPP as set out in the prospectus sent to Eligible Shareholders on 16 July 2025 remain unchanged.
Enquiries
A copy of the Prospectus is available via the Company’s website at www.imugene.com or can be obtained by contacting the Company’s Share Registry on the number noted below.
For further information relating to the Offer, please contact the Company’s Share Registry, Automic Registry Service Limited, on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia), at any time between 8:30am and 5:30pm (AEST), Monday to Friday (excluding public holidays) until the closing date of the SPP and Options Offer.
For more information please contact:
Leslie Chong Managing Director and Chief Executive Officer
General Investor Enquiries
Media Enquiries
Matt Wright [email protected]
Connect with us on LinkedIn @Imugene Limited Follow us on Twitter @TeamImugene Watch us on YouTube @ImugeneLimited
About Imugene (ASX:IMU)
Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene
IMUGENE LIMITED ACN 009 179 551
2
==> picture [42 x 42] intentionally omitted <==
zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T’s for solid tumours and B-cell vaccine candidates. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally. Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Together with leading specialists and medical professionals, we believe Imugene’s immunooncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.
Release authorised by the Executive Chairman.
Not an offer in the United States
This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements under the US Securities Act and applicable US state securities laws.
IMUGENE LIMITED ACN 009 179 551
3